What is Hemovent?
Based in Aachen, Germany, Hemovent specializes in the development of intuitive, mobile ECMO technology. The company addresses a critical gap in the MedTech sector by creating heart-lung support systems that prioritize mobility and ease of use, even in environments lacking stable power infrastructure. With over 25 years of collective expertise, Hemovent is redefining the standard for patient stabilization. Their core product line, including the MOBYBOX and MOBYO, serves as a testament to their commitment to clinical efficacy and safety, positioning the firm as a key player in the global critical care market. By simplifying complex medical procedures, Hemovent is effectively lowering the barrier to entry for advanced life support in emergency medicine.
How much funding has Hemovent raised?
Hemovent has raised a total of $13.5M across 3 funding rounds:
Grant
$810K
Series A
$2M
Series B
$10.7M
Grant (2017): $810K, investors not publicly disclosed
Series A (2017): $2M led by KfW Group, WCTI Partners, Seed Fonds Aachen II, MIG Verwaltungs AG, First Capital Partner GmbH, and NRW.BANK.Venture Fonds
Series B (2020): $10.7M supported by MIG Funds
Key Investors in Hemovent
MIG Verwaltungs AG
MIG Capital is a Munich-based venture capital firm that primarily invests in innovative ideas across Europe, focusing on startups in the Life Sciences and Deep Tech sectors.
KfW Group
Headquartered in Frankfurt, Germany, KfW IPEX Bank is a subsidiary of the KfW Banking Group that finances international and export projects within the KfW Group.
Seed Fonds Aachen II
A regional investment vehicle focused on supporting early-stage technology and life science ventures within the Aachen innovation ecosystem.
What's next for Hemovent?
With the recent infusion of capital, Hemovent is poised to transition from a development-focused entity to a major enterprise-level player in the global medical device market. The strategic roadmap likely includes aggressive international regulatory filings and the expansion of their clinical footprint across Europe and beyond. As the company scales, the focus will remain on enhancing the MOBYBOX ecosystem to ensure it remains the gold standard for mobile patient stabilization. Investors are closely watching how this capital will be deployed to optimize supply chain resilience and drive further innovation in the life sciences sector, ultimately aiming to improve patient outcomes in high-acuity settings.
See full Hemovent company page
